Nourinia R, et al. - Researchers evaluated the impact of intravitreal injection of bevacizumab on central choroidal thickness (CCT) and its association with central macular thickness (CMT) and best-corrected visual acuity (BCVA) changes in eyes with center-involving diabetic macular oedema. The mean age of the patients involved was 63.1 ± 8.0 (range, 52–75) years. As per data, CCT decreased after treatment of diabetic macular oedema with intravitreal injection of bevacizumab. This reduction significantly correlated with CMT reduction and vision improvement.